Regen BioPharma, Inc. (OTCMKTS:RGBP – Get Free Report) saw a large increase in short interest in the month of May. As of May 29th, there was short interest totaling 339,948 shares, an increase of ∞ from the May 14th total of 0 shares. Based on an average trading volume of 47,702,080 shares, the short-interest ratio is presently 0.0 days.
Regen BioPharma Price Performance
OTCMKTS RGBP opened at $0.00 on Tuesday. Regen BioPharma has a 12 month low of $0.00 and a 12 month high of $0.12.
About Regen BioPharma
Regen BioPharma, Inc is a development‐stage biotechnology company focused on advancing regenerative medicine and immunotherapy products through stem cell science. The company’s research efforts center on identifying and developing novel therapeutic candidates that harness the regenerative potential of adult and embryonic stem cells, with an emphasis on cancer, infectious and autoimmune diseases.
Its primary activities include the discovery and preclinical validation of stem cell‐derived receptors and peptides, the development of immuno‐oncology assets, and the filing of investigational new drug (IND) applications to support first‐in‐human studies.
See Also
- Five stocks we like better than Regen BioPharma
- These 5 Companies Just Made a Massive Bet on Themselves
- 5 Stocks Built to Thrive in a Higher-for-Longer Economy
- RH’s Strong Q1 Still Leaves Investors With One Big Question
- Iran Ceasefire or Not, These 3 Companies Could Win
Receive News & Ratings for Regen BioPharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regen BioPharma and related companies with MarketBeat.com's FREE daily email newsletter.
